Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd and keeping the price target at CHF6.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising results from the pivotal trial of aprocitentan, which demonstrated significant benefits for patients with chronic kidney disease and resistant hypertension. The drug, which targets the endothelin pathway, showed a substantial reduction in both blood pressure and proteinuria, a marker of kidney damage, without increasing the risk of hyperkalemia. This positions aprocitentan as a valuable therapeutic option in a population with limited treatment choices.
Additionally, the potential for a U.S. partnership to commercialize aprocitentan is seen as a key future value driver for Idorsia. The drug’s inclusion in the ACC/AHA Guidelines for hypertension management and positive feedback from real-world prescribers further bolster its market potential. The valuation of Idorsia, based on a discounted cash flow methodology, reflects the anticipated success of aprocitentan alongside other approved drugs, leading to a price target of CHF6 per share.
In another report released on December 1, Kepler Capital also upgraded the stock to a Buy with a CHF4.50 price target.